ArticleFrontiers in medicine2026
Integrating network pharmacology, molecular docking and dynamics simulation to decipher the antipyretic mechanisms of Xiaochaihu granules.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Xiao-Chai-Hu granules (XCHG), a classical traditional Chinese medicine formula derived from the ancient text Erta Treatise on Febrile Diseases, has demonstrated established clinical efficacy in fever management; however, the underlying antipyretic mechanism remains incompletely understood. Methods: This study employed an integrated computational-experimental approach combining network pharmacology, molecular docking, molecular dynamics (MD) simulation, and cellular validation to systematically elucidate XCHG's mechanism of action. Functional validation was performed in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages using nitric oxide (NO) assay, enzyme-linked immunosorbent assay (ELISA), quantitative real-time polymerase chain reaction (qRT-PCR), and Western blot analysis. Results: Through analysis of 18 pharmacokinetically validated blood-absorbed components, we identified 120 fever-related targets, from which 17 core targets and 5 key bioactive compounds (Oroxylin A, Wogonin, Baicalein, Liquiritigenin, and Enoxolone) were screened. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed that XCHG modulates inflammation, immune regulation, and key signaling pathways including PI3K-Akt, MAPK, and EGFR tyrosine kinase inhibitor resistance. Molecular docking identified three high-affinity component-target pairs: EGFR-Enoxolone (-9.3 kcal/mol), ESR1-Liquiritigenin (-8.7 kcal/mol), and SRC-Baicalein (-8.4 kcal/mol), with 100-ns MD simulations confirming the structural stability and binding persistence of these complexes. In LPS-stimulated RAW264.7 macrophages, XCHG dose-dependently inhibited NO production and suppressed pro-inflammatory mediators (TNF- Conclusion: Mechanistically, XCHG exerts comprehensive intervention across the inflammatory-pyrogenic axis through a dual mechanism: upstream blockade of EGFR-SRC signaling coupled with ESR1-mediated immune homeostasis restoration, distinguishing it from conventional single-target antipyretics. This study provides systematic mechanistic insights supporting the evidence-based clinical application of XCHG and establishes a replicable methodological framework for investigating complex herbal formulas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.